Platelet glycoprotein IIb/IIIa inhibition in acute coronary syndromes

Current Cardiology Reports

Volumn 1, Issue 3, 1999, Pages 199-205

  Mak, Koon Hou ^a   Moliterno, David J ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETIC ACID DERIVATIVE; ANTITHROMBOCYTIC AGENT; DRUG DERIVATIVE; EPTIFIBATIDE; FIBRINOGEN RECEPTOR; LAMIFIBAN; PEPTIDE; TIROFIBAN; TYROSINE;

ACUTE DISEASE; BLEEDING; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG ANTAGONISM; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; MORTALITY; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK FACTOR; SURVIVAL;

ACETATES; ACUTE DISEASE; HEMORRHAGE; HUMANS; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA; PEPTIDES; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS; SURVIVAL ANALYSIS; TYROSINE;

EID: 0033187270     PISSN: 15233782     EISSN: 15343170     Source Type: Journal    
DOI: 10.1007/s11886-999-0023-y     Document Type: Article

References (28)

1. Théroux P, Ouimet H, McCans J, et al.: Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med 1988, 319:1105-1111.
2. The RISC Group: Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet 1990, 336:827-830.
3. Lewis HD Jr, Davis JW, Archibald DG, et al.: Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study. N Engl J Med 1983, 309:396-403.
4. Cairns JA, Gent M, Singer J, et al.: Aspirin, sulfinpyrazone, or both in unstable angina. Results of a Canadian multicenter trial. N Engl J Med 1985, 313: 1369-1375.
5. Cohen M, Adams PC, Parry G, et al. and the Antithrombotic Therapy in Acute Coronary Syndrome Research Group: Combination antithrombotic therapy in unstable rest angina and non-Q-wave myocardial infarction in nonprior aspirin users. Primary end point analysis for the ATACS Trial. Circulation 1994, 89:81-88.
6. Oler S, Whooley MA, Oler J, Grady D: Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. JAMA 1996, 276:811-815.
7. Vetrovec GW, Cowley MJ, Overton H, Richardson DW: Intracoronary thrombus in syndromes of unstable myocardial ischemia. Am Heart J 1981, 102: 1202-1208.
8. Capone G, Wolf NM, Meyer B, Meister SG: Frequency of intracoronary filling defects by angiography in angina pectoris at rest. Am J Cardiol 1985, 56:403-406.
9. Freeman MR, Williams AE, Chisholm RJ, Armstrong PW: Intracoronary thrombus and complex morphology in unstable angina. Circulation 1989, 80:17-23.
10. TIMI IIIB Investigators: Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction: results of the TIMI IIIB trial. Circulation 1994, 89:1545-1556.
11. Moliterno DJ, Sapp SK, Topol EJ: The paradoxical effect of thrombolytic therapy for unstable angina: metaanalysis [abstract]. J Am Coll Cardiol 1994, 23:288A.
12. Coller BS, Peerschke EI, Scudder LE, Sullivan CA: A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic-like state in normal platelets and binds to glycoprotein IIb and/or IIIa. J Clin Invest 1983, 72:325-338.
13. EPIC Investigators: Use of monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk patients. N Engl J Med 1994, 330:956-961.
14. EPILOG Investigators: Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997, 336:1689-1696.
15. IMPACT-II Investigators: Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Lancet 1997, 349:1422-1428.
16. RESTORE Investigators: Effects of platelet glycoprotein IIb/ IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation 1997, 96:1445-1453.
17. EPISTENT Investigators: Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet 1998, 352:87-92.
18. Théroux P, Kouz S, Roy L, et al.: Platelet membrane receptor GP IIb/IIIa antagonism in unstable angina. The Canadian Lamifiban study. Circulation 1996, 94:899-905.
19. PARAGON Investigators: International randomized controlled trial of Lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina. Circulation 1998, 97:2386-2395.
20. Moliterno DJ, Harrington RA, Newby KL, et al.: Late diverging event curves for survival following IIb/IIIa antagonism in patients with unstable angina: PARAGON 1-year follow-up [abstract]. J Am Coll Cardiol 1998, 31:208A.
21. Steiner B, Hofer U, Wittke B, et al.: Plasma level of lamifiban and platelet receptor occupancy best predict clinical outcome in patients with unstable angina: results from PARAGON A [abstract]. Circulation 1998, 98:I-561.
22. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators: Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 1998, 338:1488-1487.
23. The Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators: A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med 1998, 338:1498-1505.
24. PURSUIT Investigators: Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 1998, 339:436-443.
25. Kong DF, Califf RM, Miller D P, et al.: Clinical outcomes of therapeutic agents that block the platelet glycoprotein inhibitor integrin in ischemic heart disease. Circulation 1998, 98:2829-2835.
26. Lincoff AM, Califf RM, Anderson KM, et al.: Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein II/IIIa receptor blockade by abciximab (c7E3 Fab) among patients with unstable angina undergoing percutaneous coronary resvascularization. J Am Coll Cardiol 1997, 30:149-156.
27. Topol EJ, Ferguson JJ, Weisman HF, et al.: Long-term protection from myocardial ischemic events in a randomized trial of brief integrin betaSB3 blockade with percutaneous coronary intervention. JAMA 1997, 278:479-484.
28. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study. Lancet 1997, 349:1429-1435.